GlaxoSmithKline Recalls H1N1 Vaccine in Canada Over ‘Life-Threatening’ Allergy Risk
LONDON — The pharmaceutical company GlaxoSmithKline says it has advised medical staff in Canada to not use one batch of swine flu vaccine for fear it may trigger life-threatening allergies.
GlaxoSmithKline spokeswoman Gwenan White said Tuesday the company issued the advice after reports that one batch of the swine flu vaccine might have caused more allergic reactions than normal.
She says the affected batch contains 172,000 doses of the vaccine. She declined to say how many doses had been administered before the advice to stop using them was given.
White says GlaxoSmithKline wrote to Canadian healthcare professionals advising them to stop using the batch on Nov. 18. She says a total of 7.5 million doses of the vaccine have been distributed in Canada.
